

Dr. Kirsten Müller-Vahl, M.D., is a Professor of Psychiatry at the Department of Psychiatry, Socialpsychiatry and Psychotherapy at the Hannover Medical School (MHH), Germany. She is a specialist in both neurology and adult psychiatry. Since 1995, she is the head of the Tourette syndrome outpatient department at the MHH. From 1997 to 2003 she was a grant holder of the German government (Dorothea-Erxleben-Stipendium) for scientific research related to Tourette syndrome. From 2012-2016, she was the vice president of the European Society of the study of Tourette syndrome (ESSTS). Since 1998 she is a member and 2. Chairwoman of the national German Association for Cannabinoid Medicines (ACM). She is a founding member (2000) of the International Association for Cannabinoid Medicines (IACM), has been the 1. Chairwoman of the IACM (2007-2009) and is presently the Vice President of the IACM (since 2015). Since 2016 she is a member of the committee of experts for narcotic drugs at the federal opium bureau of the Federal Institute for Drugs and Medical Devices (BfArM) in Germany. In 2017, she was invited as an expert to the German Bundestag for a hearing for the German cannabis law.

Her scientific work related to Tourette syndrome included several clinical studies as well as controlled trials on the effects of different types of treatment on tics including cannabis-based medicines. In 2015, the German Research Foundation (DFG) approved a large multicentre randomized controlled trial for funding investigating the efficacy and safety of nabiximols (Sativex®) in the treatment of adult patients with TS (CANNA-TICS, NCT03087201). In 2018, she was PI of a phase 1b study investigating efficacy and safety of ABX-1431, a first-in-class, small-molecule inhibitor of monoacylglycerol lipase (MGLL), in adult patients with Tourette syndrome (NCT03058562). Currently, she is the PI of a phase 2, multi center follow-up study using ABX-1431 in Tourette syndrome (NCT03625453).

At the 9th IACM Conference on Cannabinoids in Medicine 2017 she received the IACM Award 2017 for Clinical Research for her special achievements regarding the re-introduction of cannabis and cannabinoids as medicine.

Dr. Müller-Vahl has published over 100 scientific articles, is the author of several book chapters and the leading German textbook on Tourette syndrome, reviewed a large number of scientific articles for several peer-reviewed journals, is associate editor of the journal "Cannabis and Cannabinoid Research", and editorial board member of the Journal "Medical Cannabis and Cannabinoids".